The honest summary of ibogaine research is this: the findings are consistently encouraging, and the evidence base is small.
Ibogaine has been studied for six decades, but almost never in the way modern medicine requires. There are no large randomised controlled trials, no regulatory approvals anywhere in the world, and much of what exists is observational — describing what happened in particular clinics rather than testing the compound against a control group.
That is a genuine limitation, and anyone who tells you otherwise is selling something. It is also not the same as an absence of evidence. This page sets out what has actually been published, what it demonstrates, what it cannot demonstrate, and why the gap exists.
Two of the studies described below were co-authored by Dr. Bruno Rasmussen (published as Bruno Rasmussen Chaves).
Why the evidence base is small
The shortage of ibogaine research is not primarily a scientific verdict. It is a legal one.
Where a compound is prohibited, formal trials become extremely difficult to run: research approval is harder, supply is restricted, and funding is scarce. Meanwhile treatment does not stop — it moves into unregulated settings that produce no usable data, and where the harm that does occur is poorly documented.
The result is a distorted picture. Decades of clinical use have generated far more experience than published evidence, and the countries where ibogaine is not banned are the only places where systematic data has been gathered at all.
This is beginning to shift. Interest in ibogaine as a response to the opioid crisis has grown, and public funding has been committed in the United States toward formal clinical trials — the first serious move toward the kind of research that approval would require.
Ibogaine legality by country →
The published Brazilian studies
Brazil has produced the most substantial clinical data on ibogaine, for a specific reason: ibogaine is not a controlled substance there, so treatment has taken place openly in hospitals — and open treatment can be studied.
Two peer-reviewed studies came out of a hospital-based programme in Santa Cruz do Rio Pardo, São Paulo state, both co-authored by the physician running it, Dr. Bruno Rasmussen. Three Brazilian universities took part in the research: UNIFESP, UNICAMP and UFABC.
The retrospective study (2014)
Schenberg EE, de Castro Comis MA, Rasmussen Chaves B, da Silveira DX. “Treating drug dependence with the aid of ibogaine: A retrospective study.” Journal of Psychopharmacology, 2014. DOI 10.1177/0269881114552713
What it did. A retrospective analysis of 75 patients treated for alcohol, cannabis, cocaine and crack dependence — 72% of whom were polydrug users. Treatment combined a single supervised ibogaine session with psychotherapy before and after.
What it found.
- 61% of participants were abstinent at follow-up
- Patients treated once reported a median of 5.5 months of abstinence
- Patients treated more than once reported a median of 8.4 months
- The difference was statistically significant (p < 0.001), and both groups showed longer abstinence than before their first ibogaine session (p < 0.001)
- No serious adverse reactions and no fatalities
What the authors concluded. That physician-supervised ibogaine accompanied by psychotherapy can facilitate prolonged periods of abstinence without fatalities or complications, and that it may be a safe and effective treatment for dependence on stimulants and other non-opiate drugs.
What it cannot tell you. This was a retrospective review of one programme, not a randomised controlled trial: there was no control group, so it cannot separate the effect of ibogaine from the effect of the psychotherapy, the screening, or the motivation of people willing to travel and abstain for weeks beforehand. And the cohort was non-opioid — the findings should not be read as opioid outcomes.
The qualitative study (2016)
Schenberg EE, de Castro Comis MA, Alexandre JFM, Rasmussen Chaves BD, Tófoli LF, da Silveira DX. “Treating drug dependence with the aid of ibogaine: A qualitative study.” Journal of Psychedelic Studies, 2016. DOI 10.1556/2054.01.2016.002
Why it exists. Because measuring drug use alone is an inadequate way to evaluate addiction treatment. Current recommendations call for secondary outcomes as well — craving, family and social relationships, quality of life, and self-efficacy. A patient who has stopped using but whose life has not improved has not really been treated.
What it did. A directed qualitative content analysis of semi-structured patient interviews, following treatment that combined ibogaine with cognitive-behavioural therapy.
What it found. Patients reported benefit across all the secondary outcomes measured: reduced craving, and improvements in personal relationships, quality of life and self-efficacy — the sense of being able to manage one’s own behaviour.
What it cannot tell you. Qualitative research captures patient experience in depth; it does not measure effect size, and self-reported interviews are subject to the expected biases. It complements the quantitative work rather than confirming it.
Why it matters anyway. Together the two studies address a question that outcome percentages alone cannot: not only whether people stopped using, but whether their lives changed.
What the wider literature covers
Beyond these two studies, the published literature falls into several strands.
Observational studies of treatment outcomes in clinics across several countries, generally reporting reductions in opioid withdrawal and craving. These share the same limitation: no control groups.
Case series on adverse events and fatalities, which have been essential to understanding ibogaine’s risk profile. Reviews of reported deaths have consistently pointed to cardiac mechanisms — QT-interval prolongation is the most accepted explanation — and have found significant pre-existing conditions in many cases. This literature is why modern protocols require ECG and blood screening.
Pharmacological research on how ibogaine acts: its conversion to the long-acting metabolite noribogaine, its activity across multiple receptor systems, and its inhibition of hERG potassium channels, which explains the cardiac effect.
Preclinical and mechanistic work, including investigation of whether ibogaine promotes neuroplasticity. This is an active and promising line of research — but it remains a hypothesis under investigation, not an established explanation.
Is ibogaine safe? → · How ibogaine works →
How to read ibogaine claims critically
Four questions separate reliable claims from marketing, and they work on any source — including this one.
- Was it published in a peer-reviewed journal? A clinic’s internal statistics are not research. Ask for the citation.
- Was there a control group? Without one, you cannot know what the compound contributed versus everything surrounding it.
- Which substance, and how many patients? A finding in 75 stimulant-dependent patients does not automatically transfer to opioid dependence — the pharmacology and the risks differ.
- How was “success” defined, and over what period? Abstinence at three months and abstinence at two years are very different claims, and are often reported as though they were the same.
If a clinic claims a success rate without answering all four, the number is not information.
Ibogaine success rates explained →
What research is still needed
The gaps are well understood within the field.
Randomised controlled trials remain the central absence, particularly for opioid dependence, where ibogaine is most used and least formally studied. Long-term follow-up beyond a year is scarce. Dosing has never been standardised across protocols. And the cardiac safety data would benefit from systematic study, as the authors of the 2014 paper themselves noted when calling for further work on ibogaine’s effect on the ECG.
Formal trials are now beginning to be funded. Realistically, the timeline for any regulatory approval is measured in years, not months.
What this means for someone considering treatment today is straightforward and uncomfortable: you are making a decision on incomplete evidence. That is a legitimate decision to make — people do it in medicine regularly — but it should be made knowingly, and with an accurate view of what is and isn’t established.
Our position on the evidence
We are not a clinic, and we would rather lose a client to an honest answer than gain one with an overstated number.
So: ibogaine is not proven in the sense that an approved medicine is proven. The published data is encouraging, the clinical experience of physicians working with it lawfully over decades is substantial, and both fall short of what a randomised trial would establish.
What we can do is make sure you are choosing among programmes that operate to the standard the research describes — medical screening, physician supervision, and psychotherapy as part of the treatment rather than an optional extra.
Free and confidential. We’ll set out honestly what’s known and unknown for your situation — usually within 24 hours.